Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 03, 2025 14:30 ET | Source: Biofrontera Inc.

Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book

Biofrontera received patent approval for the revised formulation of Ameluz® in April 2025, extending patent protection through to December 2043.The Orange Book is published by the U.S. Food and Drug...
May 15, 2025 12:17 ET | Source: Biofrontera Inc.

Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

Biofrontera has received patent approval for the revised formulation of Ameluz®, which extends patent protection through to December 2043Ameluz PDT offers the potential for effective treatment of...
October 07, 2024 08:45 ET | Source: Biofrontera Inc.

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment

Approval allows for larger field treatment of actinic keratosis (AK) on face and scalp with Ameluz®-PDT using the BF-RhodoLED or the RhodoLED XL lampSupplemental New Drug Application (sNDA) supported...